(12) **Translation of European patent specification**

(11) **NO/EP 2970964 B1**

NORWAY

(19) NO

(51) Int Cl.

C12N 15/11 (2006.01) ***A61P 21/00 (2006.01)***
A61K 31/7088 (2006.01) ***C12N 15/113 (2010.01)***

Norwegian Industrial Property Office

(21)	Translation Published	2019.05.13
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.12.26
(86)	European Application Nr.	14723583.2
(86)	European Filing Date	2014.03.14
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2013.03.14, US, 201361782706 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
(73)	Proprietor	Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142, USA
(72)	Inventor	BESTWICK, Richard, K., 15052 Fall River Dr., Bend, OR 97707, USA FRANK, Diane, Elizabeth, 6049 34th Ave NE, Seattle, WA 98115, USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY**

(56) References Cited:

WO-A1-2010/048586, US-A1- 2010 168 212, WO-A1-2012/029986,
JERRY R. MENDELL ET AL: "Gene therapy for muscular dystrophy: Lessons learned and path forward", NEUROSCIENCE LETTERS, vol. 527, no. 2, 17 May 2012 (2012-05-17), pages 90-99, XP055128775, ISSN: 0304-3940, DOI: 10.1016/j.neulet.2012.04.078
VAN VLIET LAURA ET AL: "Assessment of the feasibility of exon 45-55 multiexon skipping for duchenne muscular dystrophy", BMC MEDICAL GENETICS, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 1 December 2008 (2008-12-01), page 105, XP021042784, ISSN: 1471-2350, DOI: 10.1186/1471-2350-9-105
FOSTER H ET AL: "Genetic therapeutic approaches for Duchenne muscular dystrophy", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 23, no. 7, 30 May 2012 (2012-05-30), pages 676-687, XP002688790, ISSN: 1043-0342, DOI: 10.1089/HUM.2012.099 [retrieved on 2012-05-30]
MOULTON H M ET AL: "Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, vol. 1798, no. 12, 17 February 2010 (2010-

02-17), pages 2296-2303, XP027430152, ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2010.02.012 [retrieved on 2010-02-17]
POPPLEWELL L J ET AL: "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials", NEUROMUSCULAR DISORDERS, PERGAMON PRESS, GB, vol. 20, no. 2, 15 January 2010 (2010-01-15), pages 102-110, XP026878306, ISSN: 0960-8966 [retrieved on 2010-01-15]

Patentkrav

1. Antisenseoligonukleotid som har følgende struktur:



hvori

A=  , C=  , G=  og T=m^{5}U=  ,

og

hvori ^ = stereokjemien til fosforsenteret ikke er definert; eller et farmasøytisk akseptabelt salt derav.

2. Farmasøytisk sammensetning som omfatter antisenseoligonukleotidet ifølge krav 1 og en farmasøytisk akseptabel bærer.

3. Sammensetningen ifølge krav 2 for anvendelse ved behandling av Duchenne-muskeldystrofi.